Mayo, 2bPrecise join to develop genomics-based CDS tools
The Mayo Clinic will work with a precision medicine company to develop and research a genomics-based care protocols approach.
The well-known delivery system has signed a license agreement with 2bPrecise, a Pittsburgh-based company that offers an EHR-agnostic cloud-based precision medicine platform.
The partners will use the 2bPrecise platform and combine it with Mayo Clinic’s knowledge and electronic phenotyping algorithms to further develop clinical protocols, which will be incorporated into the platform.
Initial work will be used to apply research to measure outcomes in patients who have cardiovascular genetic disease.
The two organizations will begin their collaboration by bringing Mayo Clinic's algorithm for FH into the 2bPrecise platform to derive insights from combined clinical and genomic research data. The collaboration aims to empower clinical researchers with the ability to test and validate new protocols based on clinical-genomic insights, with the ultimate goal of making these protocols available for optimized decision-making at the point of care.
The 2bPrecise platform harmonizes clinical and genomic information to extract patient-specific insights and present them in an actionable way to the clinician, within their current EHR workflow, overlaying knowledge sources to guide and enable clinical genomics at point of care.
Executives of 2bPrecise say they selected Mayo Clinic for this work because of their strong subject matter expertise and work in the area of clinical genomics, specifically their research in familial hypercholesterolemia (FH), and for their desire to share their care algorithms more broadly with the medical community.
“Mayo Clinic has a very robust genomics research discipline,” says Assaf Halevy, founder and CEO of 2bPrecise. “We are excited to collaborate with premier organizations like Mayo Clinic to advance genomic science and help make it clinically actionable.”
Mayo Clinic has a financial interest in the technology, with executives saying they plan to use any revenue it receives to support its not-for-profit mission in patient care, education and research.